**INTRODUCTION:** Explantation after prosthetic breast reconstruction may be performed due to various reasons including postoperative complications and patient request. The goals of this study were (1) to characterize a cohort of patients with device explantation after prosthetic breast reconstruction, (2) to perform a time based analysis of explantation, (3) to identify reasons for premature explantation, and (4) to review the bacteriology associated with explanted devices.

**METHODS:** Retrospective review of a prospectively maintained database was performed to identify patients who underwent two stage prosthetic breast reconstruction with expanders and implants, followed by explantation. Patient characteristics, surgical technique, adjuvant therapies, reason for explantation, postoperative complications, culture data was obtained. Data was analyzed according to timing of explantation (0--30 days, \>30 days, after stage I, after stage II).

**RESULTS:** A total of 55 devices (78% tissue expanders, 22% implants) in 43 patients underwent explantation during the study period. Reasons for explantation was infection (58%), patient request (22%), and wound related complications (20%). Of explants due to patient request, a contralateral explantation due to a complication was the most frequent reason (34%). Majority of explantations occurred after 30 days (62%), and after Stage I (81%). Median days to explantation was 62. No differences were observed when patient characteristics and surgical details were compared in early vs late explant groups. Older age *(p=0.01*) and high BMI *(p=0.04*) were found to be significant predictors of explantation for Stage I explantation when compared to Stage II. Among patients who underwent radiation, infection was the most common indication for device removal, with most explants occurring after adjuvant radiation therapy (64%). The most commonly cultured organisms were S.epidermidis (n=6, 10.9%), S.Aureus (n=6, 10.9%) and P.aeruginosa (n=6, 10.9%). Antibiotic resistance was commonly encountered for ampicillin, cefazolin, penicillin, and erythromycin.

**CONCLUSION:** Infection is the most common reason for explantation after prosthetic breast reconstruction. Patients should be carefully monitored for a prolonged period of time after Stage I, as majority of the explantations occur in this stage but beyond 30 days. For oral treatment, fluoroquinolones and trimetoprim-sulfametoxazol and; for IV treatment a combination of vancomycin or daptomycin with piperacillin-tazobactam or imipenems/carbapenems appear to be appropriate choices according to our culture and sensitivity results.
